Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor)

Related Clinical Trial
A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals COPD Exacerbation Blood and Urine Biomarkers Study Alpha-1 Carrier Genomics Study Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype Study of ARO-AAT in Normal Adult Volunteers Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry Respreeza® Self-administration and Learning Program (AmAREtTI Study) Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Environment Effect on Six-Minute Walk Test Performance Alpha-1 Foundation DNA and Tissue Bank Alpha1-antitrypsin Deficiency Registry Alpha-1 Research Registry Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency Alpha-1 Coded Testing(ACT) Study Long-Term Follow-up Study of ADVM-043 Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation” EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency Alpha-1 Foundation Research Registry Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients Evaluate Efficacy and Safety of “Kamada-AAT for Inhalation” in Patients With AATD A Study of DCR-A1AT in Healthy Adult Volunteers and Patients With A1ATD-Associated Liver Disease Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor) Aralast alpha1-proteinase Inhibitor Surveillance Study Pharmacokinetic Study of ARALAST (Human Alpha1- PI) The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Brief Title

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

Official Title

The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (ARALAST) Alpha1-Proteinase Inhibitor (α1-PI) on the Level of α1-PI and Other Analytes in the Bronchoalveolar (BAL) Epithelial Lining Fluid (ELF)

Brief Summary

      The purpose of this study is to evaluate the effects of weekly augmentation therapy with
      ARALAST Fraction IV-1 (Fr IV-1) on epithelial lining fluid (ELF) alpha 1-proteinase inhibitor
      levels and other ELF analytes and to assess the safety of the treatment. Eligible subjects
      with a diagnosis of severe congenital alpha 1-antitrypsin deficiency will receive 8
      consecutive weekly treatments with 60 mg/kg/week of functional ARALAST Fr IV-1 administered
      intravenously. The efficacy and safety assessments will include two bronchoscopies with
      bronchoalveolar lavage on study initiation and on study termination and multiple imaging and
      laboratory safety assessments. Each subject will participate for a minimum of 12 weeks.

Study Phase

Phase 4

Study Type


Primary Outcome

Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level

Secondary Outcome

 Ratio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels


Alpha 1-Antitrypsin Deficiency


Alpha1-Proteinase Inhibitor


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 2006

Primary Completion Date

December 2007

Eligibility Criteria

        Inclusion Criteria:

          -  Signed and dated informed consent.

          -  Male or female 18 years of age or older.

          -  Documented, endogenous serum α1-PI level < 40 mg/dL measured at screening (unless
             otherwise approved by the Sponsor) after a minimum of 28-day washout of any prior
             replacement therapy (if applicable).

          -  Phenotype Pi Z (which includes Pi*Z/Z, Pi*Z/Null, or Pi*Malton/Z), or Pi*Null/Null.

          -  Pulmonary functions at screening meeting the following criteria:

               1. Forced expiratory volume at 1 second (FEV1) >= 50% of predicted value; or

               2. FEV1 > 35% of predicted value and diffusing capacity for carbon monoxide > 45% of
                  predicated value, with no supplemental oxygen therapy and < 3 pulmonary
                  exacerbations or bronchitis requiring antibiotics/corticosteroids within the past
                  12 months).

          -  For any female of childbearing potential, a negative urine test for pregnancy within 7
             days prior to the first bronchoalveolar lavage (BAL) visit and agreement to employ
             adequate birth control measures for the duration of the study.

          -  No clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG)
             performed at the screening visit (ECG previously obtained within the past 12 months
             may be used, if available).

          -  Laboratory results obtained at the screening visit, meeting the following criteria:

               1. Serum alanine aminotransferase (ALT) <= 2 times upper limit of normal (ULN)

               2. Serum aspartate aminotransferase (AST) <= 2 times ULN

               3. Serum total bilirubin <= 2 times ULN

               4. Proteinuria < +2 on dipstick analysis

               5. Serum creatinine <= 1.5 times ULN

               6. Absolute neutrophil count (ANC) >= 1500 cells/mm3

               7. Hemoglobin (Hgb) >= 10.0 g/dL

               8. Platelet count >= 105/mm3

          -  If the subject is treated with respiratory medications, such as inhaled
             bronchodilators or inhaled corticosteroids, or other chronic medications for the
             treatment of the subjects´s other medical condition(s), the subject's medication doses
             were unchanged for at least 14 days prior to the baseline BAL visit.

        Exclusion Criteria:

          -  Clinically significant pulmonary impairment, other than chronic pulmonary disease

          -  The subject has received any alpha 1 proteinase inhibitor (α1-PI) augmentation therapy
             (e.g., Prolastin, Zemaira, Aralast, or an investigational α1-PI, by any route
             including intravenous and inhaled) within 28 days prior to screening.

          -  The subject has received an investigational drug or device within 1 month prior to
             screening, or the subject is currently receiving an investigational drug or device. If
             the subject receives another investigational drug or device after enrollment, the
             subjects is to be withdrawn from the trial.

          -  Presence of clinical symptoms of any lower respiratory tract infection or acute
             pulmonary exacerbation within 14 days prior to screening.

          -  The subject has a known selective Immunoglobulin A (IgA) deficiency (IgA level less
             than 15 mg/dL) and/or antibody against IgA.

          -  The subject is pregnant or lactating, or intends to become pregnant during the course
             of the study.

          -  The subject is not a suitable candidate for a BAL procedure.

          -  Moderate or severe bronchiectasis (total daily sputum production > 10 mL).

          -  Clinically significant medical, psychiatric, or cognitive illness, or recreational
             drug/alcohol use that, in the opinion of the investigator, would affect subject safety
             or compliance.

          -  Prior history of adverse reaction to local anaesthetics, sedatives, pain control
             drugs, and other medication employed at the study center for perioperative care
             associated with the BAL procedure.

          -  Long-term use of oral or parenteral glucocorticosteroid within 28 days prior to




18 Years - N/A

Accepts Healthy Volunteers



Baxter BioScience Investigator, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Study Sponsor

Baxalta now part of Shire

Study Sponsor

Baxter BioScience Investigator, MD, Study Director, Baxter Healthcare Corporation

Verification Date

March 2011